Insmed Inc (INSM)

[read_this_n0w]

TRCA to be bought for 9$ per share in cash (US dollars) by ipsen. (double yesterday's closing price)

With warrants etc ipsen allready owned about 43% of the company. Value put on trca with this deal is 663 million US dollar.

This is the company that focusses on free IGF1 and has an optin agreement with insmed for several indications.
(iplex is igf1bp3 compound, igf1 with binding protein bp3)


http://www.reuters.com/article/marketsNews/idINN0444683820080605?rpc=44





PS IGF1 and halve of iplex is worth 663 million ?

Optin agreement still requires ipsen to pay 50% of all past and 50% of all future cost in order to get 50% of the profits of an opted in iplex indidication.

But basically free igf1 and halve of iplex is valued at the takeover number.